0Q1G · Eli Lilly and Company
980.00
CHFUnlock stock Insights
Create a free account to unlock price targets, recommendations, and commentary.
Overview
Market Cap
Fr921.03B
PE
44.70
EV/EBITDA
30.2
DIV Yield
0.6%
Payout Ratio
26%
MQV Rating
5Very Weak
As at 15/10/2026 12:00:00 AM
Price Chart
Description
- All-Companies
- Near Support
Key Fundamentals
EPS 3 yr Growth
188.80%
EBITDA Margin
48.60%
Operating Cashflow
SFr13,963m
Free Cash Flow Return
30.00%
ROIC
36.90%
Interest Coverage
N/A
Quick Ratio
1.20
Performance
52 weeks range
Low 680 - 1020
Trade Value (12mth)
US$5,398.00
1 week
113.04%
1 month
365.75%
YTD
37.06%
1 year
1782.02%
All time high
1020.00
Additional Data
Shares Outstanding (Fully Diluted)
894m
HALO Sector
Healthcare
Next Company Report Date
N/A
Next Ex Dividend Date
13-Aug-26
Next Dividend Pay Date
10-Sep-26
Reporting Currency
CHF
Short Sell (% of issue)
0.00
Health Scores
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Very Strong
Halo Model
Mqv
Very Weak
Garp
Very Weak
Mqv Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Weak
Growth
Earnings
Very Weak
Dividends
Very Weak
Quality
Capital Efficiency
Very Weak
Balance Sheet
Very Weak
Valuation
Value
Consensus
Yield
Key Stakeholders
| Name | Title |
| Lilly Endowment, Inc. | Non-Profit Organization |
| David A. Ricks | Individual |
| Employees Provident Fund (Investment Management) | Operating Division |
| OrbiMed Advisors Private Equity | Subsidiary |
| Daniel M. Skovronsky | Individual |
